Combined 18F-NaF and 18F-FDG PET/CT in the Evaluation of Sarcoma Patients

Jackson, Tatianie; Mosci, Camila; Eyben, Rie von; Mittra, Erik; Ganjoo, Kristen N.; Biswal, Sandip; Gambhir, Sanjiv S.; Iagaru, Andrei

doi:10.1097/rlu.0000000000000845

Cited by 18 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the diagnosis of bone metastases, both 18 F-FDG-PET/CT and 18 F-FDG-PET/MRI are comparable and significantly more accurate than CT and bone scintigraphy. Combined administration of 18 F-NaF/ 18 F-FDG-PET/CT may further improve skeletal disease detection [33,34]. Whole-body MRI shows better results in the detection of bone metastases/multifocality compared to 18 F-FDG-PET/CT in some studies with sensitivity rates of 94% compared to 78% and specificity rates of 76% compared to 80%, respectively [35].…”

Section: Local Tumor Assessment and Staging-"trust In T1"mentioning

confidence: 99%

Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives

Zöllner

Amatruda

Bauer

et al. 2021

JCM

148

114

View full text Add to dashboard Cite

Ewing sarcoma, a highly aggressive bone and soft-tissue cancer, is considered a prime example of the paradigms of a translocation-positive sarcoma: a genetically rather simple disease with a specific and neomorphic-potential therapeutic target, whose oncogenic role was irrefutably defined decades ago. This is a disease that by definition has micrometastatic disease at diagnosis and a dismal prognosis for patients with macrometastatic or recurrent disease. International collaborations have defined the current standard of care in prospective studies, delivering multiple cycles of systemic therapy combined with local treatment; both are associated with significant morbidity that may result in strong psychological and physical burden for survivors. Nevertheless, the combination of non-directed chemotherapeutics and ever-evolving local modalities nowadays achieve a realistic chance of cure for the majority of patients with Ewing sarcoma. In this review, we focus on the current standard of diagnosis and treatment while attempting to answer some of the most pressing questions in clinical practice. In addition, this review provides scientific answers to clinical phenomena and occasionally defines the resulting translational studies needed to overcome the hurdle of treatment-associated morbidities and, most importantly, non-survival.

show abstract

Section: Local Tumor Assessment and Staging-"trust In T1"mentioning

confidence: 99%

Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives

Zöllner

Amatruda

Bauer

et al. 2021

JCM

148

114

View full text Add to dashboard Cite

show abstract

“…[ 18 F]F-NaF PET-CT is extremely sensitive for areas of bone involvement in sarcomas. It has been proposed that a dual-tracer approach (simultaneous injection) of NaF and FDG PET may provide advantages when defining both soft tissue and bone sites of sarcoma involvement [ 65 ].…”

Section: Sarcomasmentioning

confidence: 99%

PET-CT in Clinical Adult Oncology—VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors

Fine

Covington

Koppula

et al. 2022

Cancers

View full text Add to dashboard Cite

PET-CT is an advanced imaging modality with many oncologic applications, including staging, therapeutic assessment, restaging and surveillance for recurrence. The goal of this series of six review articles is to provide practical information to providers and imaging professionals regarding the best use of PET-CT for specific oncologic indications, the potential pitfalls and nuances that characterize these applications, and guidelines for image interpretation. Tumor-specific clinical information and representative PET-CT images are provided. The current, sixth article in this series addresses PET-CT in an evaluation of aggressive cutaneous malignancies, sarcomas and neuroendocrine tumors. A discussion of the role of FDG PET for all types of tumors in these categories is beyond the scope of this review. Rather, this article focuses on the most common malignancies in adult patients encountered in clinical practice. It also focuses on Food and Drug Agency (FDA)-approved and clinically available radiopharmaceuticals rather than research tracers or those requiring a local cyclotron. This information will serve as a guide to primary providers for the appropriate role of PET-CT in managing patients with cutaneous malignancies, sarcomas and neuroendocrine tumors. The nuances of PET-CT interpretation as a practical guide for imaging providers, including radiologists, nuclear medicine physicians and their trainees, are also addressed.

show abstract

“…Sodium fluoride (NaF) PET is a technique used in detection of bone metastases. In a study by Jackson et al (31), NaF PET/CT allowed identification of more osseous metastatic lesions than FDG PET/CT in patients with soft-tissue or bone sarcomas. Combined PET/MRI has several benefits in patients with LFS, such as lack of ionizing radiation (especially beneficial in young patients with LFS) and better soft-tissue contrast resolution.…”

Section: Li-fraumeni Syndromementioning

confidence: 99%

Radiologist’s Primer on Imaging of Common Hereditary Cancer Syndromes

et al. 2019

View full text Add to dashboard Cite

Recent advances in pathology and genetics have improved our understanding of the pathogenesis of inherited and sporadic malignancies. Detailed studies of hereditary cancer syndromes-which contribute to 5%-10% of the overall cancer burden-have shed new light on the important role of genetic abnormalities in tumor metabolism, oncologic pathways, and clinicobiologic behavior. Many inherited cancer syndromes are characterized by development of pathognomonic histotypes of neoplasms in specific target organs. Cross-sectional imaging plays an integral role in diagnosis, screening, surveillance, and treatment of patients with a wide spectrum of cancer syndromes. This article focuses on the imaging spectrum of select hereditary cancer syndromes, featuring imaging features of associated common and uncommon tumors and conditions in each syndrome, along with screening and surveillance recommendations for each condition. MRI has proved to be a useful screening modality in such patients, as these patients are often young and require prolonged screening; MRI has the added advantage of better soft-tissue contrast without ionizing radiation. The whole-body MRI protocol is also briefly discussed. The radiologist is sometimes the first physician to encounter such patients, and knowledge of these syndromes can help identify these patients earlier and impact their care by timely diagnosis and intervention. This also benefits the family members, as they can also undergo genetic testing and obtain an early diagnosis and screening. ©

show abstract

Combined 18F-NaF and 18F-FDG PET/CT in the Evaluation of Sarcoma Patients

Abstract: The combined F-NaF/F-FDG PET/CT scan allows for accurate evaluation of sarcoma patients. Further evaluation of this proposed imaging modality is warranted to identify the most suitable clinical scenarios, including initial treatment strategy and evaluation of response to therapy.

Cited by 18 publications

References 21 publications

Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives

Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives

PET-CT in Clinical Adult Oncology—VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors

Radiologist’s Primer on Imaging of Common Hereditary Cancer Syndromes

Contact Info

Product

Resources

About